In this trial, women aged 25 - 55 years with BRCA1 variants, no history of breast or ovarian cancer, and no plans for prophylactic breast surgery are randomized to receive either denosumab 120 mg subcutaneously or placebo every 6 months for 5 years. Here, BRCA1 is linked to ovarian cancer.